1-(2-Hydroxyethyl)-4,6-dimethyl-2(1H)-pyrimidinone
データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
基本情報
- CAS
14716-32-6- 標準SMILES
Cc1cc(C)n(CCO)c(=O)n1- InChIKey
JLKVZOMORMUTDG-UHFFFAOYSA-N- 分子式
- C8H12N2O2
- 平均分子量
- 168.19 g/mol
- 単同位体質量
- 168.08987763
概要
nitrogen-containing heterocyclic compound; Russian patent; antiatherogenic; used for treatment of burns; used on varicose ulcer
名称と識別子
- 優先名称
- 1-(2-Hydroxyethyl)-4,6-dimethyl-2(1H)-pyrimidinone
- IUPAC
- 1-(2-hydroxyethyl)-4,6-dimethylpyrimidin-2-one
- 英語名
- xymedon
- 分子式
- C8H12N2O2
- 分子量
- 168.19
名称と別名
xymedon14716-32-6XymedoneXimedon2(1H)-Pyrimidinone, 1-(2-hydroxyethyl)-4,6-dimethyl-Ximedone9PRF0R9JSF1-(2-Hydroxyethyl)-4,6-dimethyl-2(1H)-pyrimidinoneN-(2-Hydroxyethyl)-4,6-dimethyl-2-dehydropyrimidone1-(beta-hydroxyethyl)-4,6-dimethyl-1,2-dihydro-2-oxopyrimidineRefChem:1955571-(2-hydroxyethyl)-4,6-dimethyl-1,2-dihydropyrimidin-2-one
名称をさらに表示
KSIMEDON
1-(2-hydroxyethyl)-4,6-dimethylpyrimidin-2(1H)-oneMFCD021022161-(2-hydroxyethyl)-4,6-dimethyl-pyrimidin-2-oneZINC335663-(2-hydroxyethyl)-4,6-dimethyl-3-hydropyrimidin-2-one1-(2-hydroxyethyl)-4,6-dimethylpyrimidin-2-one1-(2-Hydroxyethyl)-4,6-dimethylpyrimidin-2(1H)-one--hydrogen chloride (1/1)UNII-9PRF0R9JSF
データベース識別子
- CAS
14716-32-6- PubChem CID
- 121931
- DTXSID
DTXSID20933048- ChEMBL
CHEMBL1625385- UNII
- 9PRF0R9JSF
- Nikkaji
- J1.008.627B
物性
構造計算による物性補完中
- XLogP
- -0.5
- 極性表面積
- 52.9 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 2
- 回転可能結合数
- 2
- 重原子数
- 12
- 形式電荷
- 0
- 複雑度
- 256
物理化学的性質
- 融点
- 134.5 · 134.5-135.5 °C
- 沸点
- 298.5 · 298.5±42.0 °C(Predicted)
- 比重(密度)
- 1.19 · 1.19±0.1 g/cm3(Predicted)
- 酸解離定数(Pka)
- 14.79 · 14.79±0.10(Predicted)
化学と産業
薬理情報
MeSH Pharmacological Classification
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
Agents that reduce the frequency or rate of spontaneous or induced mutations independently of the mechanism involved.
関連反応
1 件
化合物ノート
読み込み中…